Serum Insulin-like Factor 3 Levels Are Reduced in Former Androgen Users, Suggesting Impaired Leydig Cell Capacity
Open Access
- 2 March 2021
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (7) , e2664-e2672
Abstract
Context Illicit use of anabolic androgenic steroids (AAS) is frequently observed in men and is associated with subsequent testosterone deficiency although the long-term effect on gonadal function is still unclear. Serum insulin-like factor 3 (INSL3) has been suggested to be a superior biomarker of Leydig cell secretory capacity compared to testosterone. Objective This study aimed to investigate serum INSL3 concentrations in AAS users. Methods This community-based, cross-sectional study included men aged 18 to 50 years, involved in recreational strength training and allocated to 1 of 3 groups: never-AAS users as controls (n = 44), current (n = 46), or former AAS users (n = 42) with an average duration since AAS cessation of 32 (23 ; 45) months. Results Serum INSL3 was lower in current AAS users and former AAS users than in controls, median (interquartile range), 0.04 µg/L (nondetectable [ND]-0.07 µg/L) and 0.39 µg/L (0.24-0.62 µg/L) vs 0.59 µg/L (0.45-0.72 µg/L), P less than .001. Former AAS users exhibited lower serum INSL3 levels than controls in a multivariable linear regression even after adjusting for serum total testosterone (TT) and other relevant confounders, (B) (95% CI), –0.16 µg/L (95% CI, –0.29 to –0.04 µg/L), P equal to .011. INSL3 and TT were not associated in the model, P equal to .821. Longer accumulated AAS duration (log2) was associated with lower serum INSL3 in former AAS users, (B) (95% CI), –0.08 (95% CI, –0.14 to –0.01), P equal to .022. Serum INSL3, but not inhibin B or testosterone, was associated with testicular size in a multivariate linear regression, (B) (95% CI); 4.7 (95% CI, 0.5 to 8.9), P equal to .030. Conclusion Serum INSL3 is reduced years following AAS cessation in men, independently of testosterone, suggesting persistently impaired Leydig cell capacity.Keywords
Funding Information
- Anti Doping Denmark
- Research Foundation of Rigshospitalet
This publication has 28 references indexed in Scilit:
- Prolonged hypogonadism in males following withdrawal from anabolic–androgenic steroids: an under‐recognized problemAddiction, 2015
- The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysisAnnals of Epidemiology, 2014
- Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific StatementEndocrine Reviews, 2013
- The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: Current best estimatesThe American Journal on Addictions, 2013
- Mutations in the Insulin-Like Factor 3 Receptor Are Associated With OsteoporosisJournal of Bone and Mineral Research, 2008
- Elevated End‐of‐Treatment Serum INSL3 Is Associated With Failure to Completely Suppress Spermatogenesis in Men Receiving Male Hormonal ContraceptionJournal of Andrology, 2007
- Expression of the Insulin-Like Peptide 3 (INSL3) Hormone-Receptor (LGR8) System in the Testis1Biology of Reproduction, 2006
- Insulin-Like Factor 3 Serum Levels in 135 Normal Men and 85 Men with Testicular Disorders: Relationship to the Luteinizing Hormone-Testosterone AxisThe Journal of Clinical Endocrinology & Metabolism, 2005
- The Cross-Sectional Cohort StudyEpidemiology, 2005
- Interrelationships between sex hormone-binding globulin and testosterone, 5α-dihydrotestosterone and oestradiol- 7β in blood of normal menMaturitas, 1980